Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...

The new 12-month project extends a prior two-year award for which Habegger studied mechanisms of glucagon, Glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) and ...

By Tarun Sai Lomte An expert editorial suggests that widely used diabetes and obesity drugs may help close the long-standing ...

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...

Bariatric surgery and GLP-1 drugs are associated with reductions in fat mass and a shift in body composition toward a higher ...

By Tarun Sai Lomte From laboratory models to small human trials, a new review explores whether popular metabolic drugs could help curb alcohol, nicotine, and drug use, while underscoring how much ...

Did you know that weight-loss drugs might have the potential to heal the habit of substance abuse?In a recent study published ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

GLP-1 receptor agonists were linked to a small long-term reduction in vertebral fractures in a cohort study. The retrospective study was based on electronic health records of people with type 2 ...

Please provide your email address to receive an email when new articles are posted on . Data GLP-1s may have benefits beyond glycemic control, weight loss and CVD prevention. Alzheimer's disease, ...

The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to hit the market and disrupt the medical sector. These treatments are ...

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p 54% of participants on the 24 mg dose achieved resolution of obesity (BMI C ...